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Organ radiation dose from a CT scan, calculated by CT dosimetry software, can be combined with cancer risk data to estimate cancer incidence resulting from CT exposure. We
aim to determine to what extent the use of improved anatomical representation of the adult
human body “phantom” in CT dosimetry software impacts estimates of radiation dose and
cancer incidence, to inform comparison of past and future research.

Methods
We collected 20 adult cases for each of three CT protocols (abdomen/pelvis, chest and
head) from each of five public hospitals (random sample) (January-April inclusive 2010) and
three private clinics (self-report). Organ equivalent and effective dose were calculated using
both ImPACT (mathematical phantom) and NCICT (voxelised phantom) software. BlandAltman plots demonstrate agreement and Passing-Bablok regression reports systematic,
proportional or random differences between results. We modelled the estimated lifetime
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attributable risk of cancer from a single exposure for each protocol, using age-sex specific
risk-coefficients from the Biologic Effects of Ionizing Radiation VII report.

Results
For the majority of organs used in epidemiological studies of cancer incidence, the NCICT
software (voxelised) provided higher dose estimates. Across the lifespan NCICT resulted in
cancer estimates 2.9%-6.6% and 14.8%-16.3% higher in males and females (abdomen/pelvis) and 7.6%-19.7% and 12.9%-26.5% higher in males and females respectively (chest
protocol). For the head protocol overall cancer estimates were lower for NCICT, but with
greatest disparity, >30% at times.

Conclusion
When the results of previous studies estimating CT dose and cancer incidence are compared to more recent, or future, studies the dosimetry software must be considered. Any
change in radiation dose or cancer risk may be attributable to the software and phantom
used, rather than—or in addition to—changes in scanning practice. Studies using dosimetry
software to estimate radiation dose should describe software comprehensively to facilitate
comparison with past and future research.

Introduction
Computed Tomography (CT) scanning provides an essential tool for protecting and improving health[1]. The technology is widely used to diagnose disease, define its extent, assess
response to therapy and aid in the planning and conduct of medical procedures and interventions. However, every CT scan delivers a small radiation dose to the body that is potentially
carcinogenic. Concerns about the adverse impact of this radiation dose, and a world-wide
trend towards increasing collective radiation dose[2, 3] have led to guidelines advising on the
indications for CT scanning and radiation dose,[4, 5] as well as epidemiological research on
the potential incidence and mortality of cancers resulting from exposure to CT scans within a
population.[2, 6–12]
Determining potential cancer incidence as a result of CT scan radiation exposure requires
calculations of both the radiation dose to specific organs from a CT scanning protocol, and the
risk of cancer as a result of these doses. The former can be obtained from CT scanning protocol data—radiation quantity and the anatomical location of the scan—using ‘Monte Carlo’ calculations. These calculations consider the theoretical path of a very large number of photons
entering the body undergoing scattering and absorption interactions with the tissues that they
encounter. Results can be reported as ‘absorbed dose’ (in milligrays, mGy) and ‘equivalent’
dose (in milliseiverts, mSv) to specific organs, and effective dose (mSv). The absorbed dose
depends on the physical radiation quantity and the absorption properties of the irradiated tissue. The equivalent dose goes further by taking into account the radiation type by applying a
weighting factor to the absorbed dose, which in the case of CT scanning is one. The effective
dose, as will be discussed in more detail, is a measure of stochastic health risk to the entire
body.
Many software programs (ImPACT[13], CT-Expo[14], VirtualDose[15], NCICT[16, 17],
WINDOSE[18]) are available which can efficiently calculate absorbed and equivalent organ

PLOS ONE | https://doi.org/10.1371/journal.pone.0217816 August 14, 2019

2 / 18

Changes in CT dosimetry software: Impact on organ radiation dose and cancer incidence estimates

radiation dose from CT scanning parameters. The estimation of absorbed dose requires reference data on organ mass and an anatomical representation of the human body, known as a
“phantom”[19]. Phantoms can be designed to represent an average adult male, female or hermaphrodite (representing organs of both males and females), infants or children. The type of
phantom used within dosimetry software programs vary. Phantoms may be based on mathematical models which use quadratic equations to describe organ and body structure, or more
advanced voxelised phantoms made up of 3D pixels (or voxels) created from cross sectional
medical images, or hybrid phantoms, which are a combination of both. The earlier mathematical phantoms are limited in their ability to describe detailed human anatomy, with organs represented by cylindrical, conical and elliptical and spherical surfaces, and in 2009 the
International Commission on Radiological Protection (ICRP) recommended the use of the
more anatomically correct voxelised phantoms, specifically ICRP AM and ICRP AF[20], two
phantoms representing a reference adult male (AM) and a reference adult female (AF) for the
calculation of organ radiation dose.
As the potential health effects from radiation depend not just on the quantity of absorbed
radiation but also on how sensitive that organ is to radiation, absorbed and equivalent dose are
not sufficient for measuring health risk. Rather, a tissue weighting factor can be applied to
each organ specific equivalent dose to take this biologic sensitivity into account, the sum of
which is an estimate of the stochastic health risk to the entire body. This measure, known as
effective dose (mSv), is an output of dosimetry software. Effective dose is considered an estimate of cancer risk. However, as this measure is not specific to organ, gender or any particular
age, its use should be restricted to relative comparisons of radiation exposures across populations. The preferred method for epidemiological studies estimating excess cancer incidence
and mortality as a result of CT scanning has been to multiply organ specific equivalent doses
with organ-age-sex specific attributable risk coefficients.[21] Attributable risk provides an estimate of the number of cases of cancer among exposed individuals that can be attributed to a
unit (mGy) of ionising radiation, that is, how much extra disease has been caused by the radiation exposure, or how much cancer would be prevented if the exposure were eliminated.
Studies investigating the impact of using different software and, mathematical phantoms
compared to voxelised or hybrid phantoms, have shown significant deviation in the calculated
absorbed, equivalent and effective doses [18, 22–27]. These have been attributed to variation in
anatomy between phantoms which lead to the inclusion or exclusion of specific organs and
differences in scan length even when using the same anatomical start and end positions, as
well as variation in scanner matching methods between software programs.[18] While these
studies report the impact of phantom type on the estimates of absorbed dose to specific organs
and effective dose, none has considered how differences in the calculated absorbed dose
impact estimates of cancer incidence.
The interpretation of epidemiological work often requires comparison with historical or
international data to allow commentary on trends and variation over time and/or place. However, in the context of CT dosimetry and cancer risk estimates, the change to voxelised phantoms may impact the ability to make these comparisons. In this study we aim to determine
how estimates of radiation dose and cancer incidence have changed with the move to the more
anatomically correct voxelised phantoms. We consider to what extent changing the software—
and phantom type—used to calculate radiation dose in adults impacts the estimates of 1) effective dose and organ equivalent doses among BEIR VII cancer categories[28] and 2) cancer
incidence among those exposed to these radiation doses. The software programs compared are
ImPACT[13] version 1.0.4 (developed by the scanner evaluation centre of the United Kingdom National Health Service) which uses a mathematical phantom and NCICT[16, 17] (developed by the National Cancer Institute in the USA) which uses a voxelised phantom.
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Methods
Data collection
Technical CT scan data were collected for a selection of adult diagnostic CT scanning protocols undertaken at five public hospitals in Western Australia between January 1 and April 30
2010, via the Picture Archiving and Communication System database (PACS). The PACS
database includes all scans performed at public hospitals in Western Australia. Data collection
has been described in detail previously.[29] In summary, a random sample of 20 cases were
collected for each of three protocols 1) abdomen/pelvis (CTA1) 2) chest (CTC1) and 3) head
(CTH4) for each of five tertiary and secondary public hospitals, excluding specialist satellite
centres. Where less than 20 cases were identified, all cases were retrieved. Another sample of
20 cases from each of three private stand-alone radiology practices was sourced for each protocol from a self-report survey previously reported.[30] Twenty cases per provider were used in
this study as this is the standard practice for estimating typical doses delivered by scanning
protocols, and exceeds European Guidelines on the collection of dosimetry data for development of dose reference levels for CT which recommends a minimum sample of 10 cases.[31,
32] Technical data parameters were collected for separate scanning sequences for each case
and included kilovoltage (kV), milliamperage (mA), tube rotation time, collimation width,
pitch, volume weighted CT dose index (CTDIvol), dose-length product (DLP) and scanner
model. ImPACT uses a mathematical hermaphrodite phantom “HPA18+” (1.74m, 70kg). This
phantom is a version of an earlier mathematical phantom NCRP18+ that has been adapted for
use with the ICRP 103 reference data [33]. NCICT uses the voxelised ICRP reference phantoms, ICRP AM and AF which model a reference male (1.78m, 73kg) and a reference female
(1.68m, 60kg) respectively. This study was approved by the Western Australia Department of
Health Human Research Ethics Committee and the Curtin University Ethics Committee,
which exempted the study from requiring individual patient consent. Data did not include any
identifying information.

Organ equivalent dose and effective dose
Each case was subject to one or more scanning acquisitions within a CT protocol. Organ
equivalent dose and effective dose were calculated (in mSv) for the total number of scans
within the protocol for each case using 1) ImPACT dosimetry software and 2) NCICT dosimetry software. Only helical acquisitions were included in the analysis. The input parameters,
body/head filter, the scan start and end locations and kV were required by both the NCICT
and ImPACT software. The ImPACT software calculated CTDIvol within the software based
on other input parameters, including the scanner model, mA, rotation time, pitch and collimation, whereas NCICT allowed direct input of the CTDIvol collected in the technical data for
each case. Another difference was that NCICT used a sex-specific phantom, while ImPACT
did not differentiate.
Our primary objective was to compare the dosimetry software output for ImPACT and
NCICT. Therefore, we used the same anatomical start and end positions for each analysis, irrespective of the individual CT scan length data for each case. Using the same anatomical landmarks enabled a more consistent scan position and allowed us to adapt the position for the
sex-specific analysis. We identified the appropriate sex-specific anatomical start and end positions on the NCICT phantom, and matched these as closely as possible on the ImPACT software (hermaphrodite) (Fig 1). Identifying a consistent start-end location between phantoms
was challenging due to the variation between phantom anatomy and positioning of the body,
particularly the head. Scan start-end position and phantoms are shown in Fig 1. These
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Fig 1. ImPACT and NCICT phantom scan start end positions for a) abdomen/pelvis b) chest and c) head
protocols. Start and end measurements are indicated below each phantom diagram. Length of scan is shown in
brackets. Phantom images are screenshots from ImPACT and NCICT software adapted to show stop start locations for
the three protocols.
https://doi.org/10.1371/journal.pone.0217816.g001

anatomical positions were consistent with the typical anatomical reference start-end positions
of these types of scans as identified by local medical imaging technologists[30]. CTDIvol in
conjunction with scan start-end position and kV provided all the technical data necessary for
the calculation of organ radiation dose. While the NCICT software based their dosimetry calculation on the CTDIvol, we were unable to input the CTDIvol directly into the ImPACT
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software. Rather, the ImPACT software calculated CTDIvol from other technical input. This
resulted in some variation in the CTDIvol value used for the dosimetry estimate. In order to
normalise the CTDIvol between the software programs and for CTDIvol to be consistent with
that reported in the dataset, we were required to manipulate the technical input parameters in
the ImPACT software.
ImPACT and NCICT software both generate organ specific absorbed dose (mGy), equivalent dose (mSv) and effective dose (mSv). We present the organ specific results for those
organs included in the BEIR VII risk tables to calculate total cancer incidence. These BEIR VII
categories include leukaemia (which appears as “bone marrow” in ImPACT and “active marrow” in NCICT), and the category “other”. “Other” is not a category provided by ImPACT or
NCICT. For “Other” we used the mean of the median doses for organs not named in the BEIR
VII LAR tables but which were included in the remainder organs listed by ICRP 103 [2] (S1
Table). This is an approximation and assumes each organ contributes equally to the risk.
NCICT software provided sex-specific results. For the reporting of effective dose, we averaged
the male and female effective dose for comparison with the ImPACT hermaphrodite result. As
a previous study had shown tube voltage affected the ratio of the organ and effective doses calculated by mathematical phantom software compared to the voxelised phantom software,[23]
we restricted the analysis to cases with the most commonly used tube voltage cases in each
protocol.

Statistical analysis
We report the estimated median effective dose and organ equivalent doses for the ImPACT
and NCICT software and demonstrate the agreement between the software results with BlandAltman plots. Plots are shown for effective dose (hermaphrodite) by case and organ equivalent
dose by median for each protocol for males and females. A typical Bland-Altman plot shows
the mean result on the horizontal axis with the difference between the results on the vertical
axis with two horizontal lines demonstrating the 95% limits of agreement. These limits of
agreement are based on the assumption that the differences are normally distributed, with no
relationship between the magnitude of the mean and the difference in results. As this assumption is not met for effective dose, we plot the difference between the methods as a percentage
of the NCICT result (i.e. the reference) on the vertical axis.[34, 35] The organ specific median
results are also plotted as a proportion. We present the median organ result, as it is the median,
rather than individual result that is generally used to estimate cancer incidence using BEIR VII
risk coefficients.
The values produced by the ImPACT and NCICT software were also compared using Passing-Bablok regression. Passing-Bablok regression is a robust, non-parametric (i.e. does not
rely on assumptions regarding distribution of samples) linear regression test used for method
comparison. This regression model reports on the presence of systematic differences (where
results vary by a constant amount) and proportional differences (where results vary proportionately) between the method measurements[36]. The model also reports random differences.
Random difference between measurement methods is based on the distribution of the remaining variation after correcting for proportional and systematic differences (residuals) Where
the Residual Standard Deviation (RSD) interval -1.96 RSD to +1.96 RSD is large, the methods
may not be comparable. Only organ categories that contributed at least 10% to the total number of cancers, as averaged across the lifespan (age 18–80) were analysed using Passing-Bablok
regression. A linear relationship between the data measurements is required. Where a cumulative sum linearity test (CUSUM) showed deviation from linearity, we have log transformed the
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data to approximate linearity. For some organs we were unable to approximate linearity and
therefore we have not reported the results of the regression.

Cancer risk modelling
We modelled the estimated lifetime attributable risk (LAR) of cancer inferable from a single
exposure at each age separately for males and females for each protocol. To do so, the median
specific absorbed organ dose (mGy) (equal to the equivalent dose mSv in the case of CT scanning) of each protocol (male or female) was multiplied with the age-sex specific risk coefficients from Table 12D-1 of the Biologic Effects of Ionizing Radiation (BEIR) VII report [28] to
provide the estimated number of cases of cancer per 100,000 individuals exposed at that age.
The BEIR VII risk coefficients represent the excess risk that can be directly attributable to a
unit (mGy) of ionising radiation. We report LARS for exposure at 18 to 80 years of age, at
yearly intervals. This required linear interpolation of the BEIR VII risk coefficients which are
reported in 5 yearly intervals to age 20 and then 10 yearly intervals. LAR of cancer incidence
was calculated using both the organ dose estimates from the ImPACT software and the
NCICT software.

Results
Scanning data were obtained for 160 cases for each of the abdomen/pelvis and head protocols,
and 158 cases for the chest protocol. Cases with a tube voltage of 120kV accounted for all of
the abdomen/pelvis cases, 155/158 of the chest cases and 124/160 head scan cases. Median
effective dose and median organ equivalent dose as calculated by ImPACT and NCICT dosimetry software are shown in Table 1. The relationship between the effective dose as calculated by
the ImPACT and NCICT software on a case by case basis are shown in Fig 2, showing consistently larger effective doses calculated by NCICT than ImPACT for the abdomen/pelvis and
chest protocols, and lower effective doses for the head protocol. Fig 3 shows the relationship
between the ImPACT and NCICT medians for each protocol by male and female. Along the
horizontal line is the magnitude of the NCICT median (the reference result), while the vertical
line shows the percentage difference between the two estimates relative to the NCICT median.
The organs represented below the line of equivalence (i.e. zero difference) are those for which
the NCICT median is lower than the ImPACT median. The male ImPACT and NCICT calculations of organ equivalent doses for the abdomen/pelvis protocol show a general decrease in
the percentage difference in the estimated organ dose as the magnitude of the dose increases.
The greatest percentage difference is shown for the prostate (90%) and the thyroid (84%) dose
estimates. However, the thyroid organ receives very little equivalent dose comparatively to the
other organs, and in terms of the difference in magnitude, the NCICT dose is only 0.22 mSv
higher (Table 1). This is the same for the female thyroid estimates (Table 1). The female results
also show large variation for breast (56%) with smallest variation for the stomach (11%) and
liver (14%) (Fig 3). The chest protocol (Fig 3B) shows much higher mean variation in results,
with the NCICT results that are consistently higher than the ImPACT results, with the exception of leukaemia (i.e. bone marrow) and lung dose estimates in males. The head protocol
results (Fig 3C) also show higher NCICT than ImPACT results for most organs.
The organs that contribute at least 10% to average cancer incidence over the lifespan are
shown in the shaded cells in Table 1. There were significant, although often-times small, proportional differences between the ImPACT and NCICT equivalent dose estimates for both
males and females in all protocols for all these organs (excluding those for which linearity
could not be approximated) (Table 2). Many organs also showed small significant systematic
differences. A systematic difference is one where the results differed by a constant amount. In
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Table 1. Median of the organ equivalent dose for each protocol by BEIR VII category (male and female) and effective dose (gender neutral).
Abdomen/Pelvis (n = 160)

Chest (n = 155)

ImPACT��

NCICT��

Difference�

ImPACT��

Stomach

14.00

12.70

-1.30

Colon

12.00

14.85

Liver

13.00

12.04

Lung

2.35

3.09

Prostate

12.00

Bladder
Other

Category (mGy)

Head (n = 124)

NCICT��

Difference�

ImPACT��

NCICT��

Difference�

4.00

9.55

5.55

0.00

0.05

0.04

2.85

0.16

2.88

2.72

0.00

0.02

0.02

-0.96

5.80

9.36

3.56

0.01

0.06

0.05

0.74

12.00

10.23

-1.77

0.09

0.27

0.18

6.31

-5.69

0.01

0.02

0.01

0.00

0.00

0.00

12.00

12.48

0.48

0.01

0.04

0.03

0.00

0.00

0.00

5.91

5.57

-0.34

4.45

5.15

0.70

7.80

5.83

-1.98

MALE

Thyroid

0.04

0.26

0.22

2.00

13.29

11.29

1.70

1.14

-0.56

Leukaemia

5.30

5.69

0.39

3.50

2.91

-0.59

2.60

2.22

-0.38

Stomach

14.00

15.70

1.70

4.00

6.68

2.68

0.00

0.04

0.04

Colon

12.00

16.30

4.30

0.16

0.48

0.32

0.00

0.01

0.01

Liver

13.00

15.07

2.07

5.80

11.57

5.77

0.01

0.06

0.06

Lung

2.35

3.10

0.75

12.00

12.70

0.70

0.09

0.34

0.25

Breast

0.51

1.17

0.66

9.60

11.73

2.13

0.03

0.19

0.17

Uterus

13.00

9.68

-3.32

0.04

0.05

0.01

0.00

0.01

0.01

Ovary

12.00

10.29

-1.71

0.05

0.06

0.01

0.00

0.01

0.01

Bladder

12.00

13.88

1.88

0.01

0.04

0.03

0.00

0.01

0.00

Other

6.21

6.70

0.48

4.72

6.65

1.93

8.26

5.77

-2.49

FEMALE

Thyroid

0.04

0.26

0.22

2.00

15.74

13.74

1.70

1.57

-0.13

Leukaemia

5.30

6.50

1.20

3.50

4.11

0.61

2.60

1.86

-0.74

Effective dose (mSv)

6.70

7.51

0.81

1.39

1.80

1.32

-0.48

GENDER NEUTRAL

�

5.10

6.49

Difference equals ImPACT median subtract NCICT median

��

Shaded cells are those organs that contribute on average at least 10% of the total number of cancers across the lifespan as calculated using the BEIR VII Lifetime

attributable risk coefficients for ages 18 to 80.
https://doi.org/10.1371/journal.pone.0217816.t001

evaluating Passing Bablok regression, random differences should be reported as this demonstrates if the methods are comparable. In our study no significant random differences were
identified (Table 2 confidence intervals cross zero), suggesting the methods are comparable.

Fig 2. Bland Altman Plots for effective dose for the a) abdomen/pelvis b) chest and c) head protocols.
https://doi.org/10.1371/journal.pone.0217816.g002
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Fig 3. Bland Altman Plots for median organ equivalent dose for the a) abdomen/pelvis b) chest and c) head protocols.
https://doi.org/10.1371/journal.pone.0217816.g003

The contribution of exposure to the CT scanning protocol on cancer incidence across the
lifespan is shown in Figs 4–6 using both the ImPACT and NCICT organ equivalent medians
for males and females. With the exception of the head protocol (Fig 6), in all cases, the NCICT
dosimetry estimates result in larger estimates of cancer incidence. This difference is more
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Table 2. Passing Bablok regression–Comparison of median organ equivalent doses as estimated by ImPACT and NCICT for each protocol (abdomen pelvis, chest
and head) for those organs that contribute >10% to total cancer incidence (averaged over ages 18–80) for a) males and b) females.
% contributiona
Organ

ImPACT

NCICT

Regression equationb

Differences (95% CI)
c

Systematic

Proportionald

Randome

-0.1133 (-0.19, -0.01)

1.0589 (1.04, 1.07)

0.30 (-0.59, 0.59)

0.0934 (0.09, 0.10)

1.0063 (1.00, 1.01)

0.01 (-0.01, 0.01)

-0.020 (-0.04, 0.003)

0.95 (0.95, 0.96)

0.08 (-0.15, 0.15)

y = 0.18 + 16.17 x

0.18 (0.11, 0.21)

16.17 (15.81, 16.74)

0.02 (-0.03, 0.03)

-0.14 (-0.21, -0.03)

0.84 (0.83, 0.84)

0.23 (-0.45, 0.45)

-0.13 (-0.22, -0.03)

0.95 (0.90, 0.99)

0.10 (-0.19, 0.19)

-0.13 (-0.21, -0.02)

1.18 (1.16, 1.19)

0.32 (-0.62, 0.62)

ImPACT = x, NCICT = y
Male
Abdomen Pelvis

Bladder

19

19

y = -0.11 + 1.06x

Colon

28

33

log(y) = 0.09 + 1.01 log(x)

Other

19

17

y = -0.02 + 0.95 x
Chest

Colon

<1

11

Lung

50

36

y = -0.14 + 0.84 x

Other

28

28

Cannot approx. linearityf

Leukaemia

83

80

y = -0.13 + 0.95 x

Other

15

17

Cannot approx. linearityf

Head

Female
Abdomen Pelvis
Bladder

18

18

y = -0.13 + 1.18 x

Colon

18

21

Log(y) = 0.13 + 1.01 log(x)

Lung

11

13

y = -0.01 + 1.32 x

Other

21

19

y = -0.018 + 1.09 x

0.13 (0.13, 0.14)

1.01 (1.00, 1.01)

0.01 (-0.01, 0.01)

-0.012 (-0.03, -0.00)

1.32 (1.31, 1.33)

0.05 (-0.09, 0.09)

-0.02 (-0.05, 0.01)

1.09 (1.08, 1.10)

0.09 (-0.17, 0.17)

Chest
Breast

25

25

y = 0.16 + 1.17 x

0.16 (0.08, 0.31)

1.17 (1.16, 1.18)

0.28 (-0.55, 0.55)

Lung

52

44

y = -0.17 + 1.04 x

-0.17 (-0.26, -0.03)

1.04 (1.03, 1.04)

0.25 (-0.50, 0.50)

Other

14

16

y = -0.06 + 1.43 x

-0.06 (-0.10, -0.01)

1.43 (1.42, 1.44)

0.09 (-0.17, 0.17)

-0.12 (-0.19, 0.01)

0.80 (0.74, 0.83)

0.09 (-0.18, 0.18)

Head
Leukaemia

86

78

y = -0.12 + 0.80 x

Other

10

10

Cannot approx. linearityf

a

Proportion of the total number of cancers across the lifespan as calculated using the BEIR VII Lifetime attributable risk coefficients for ages 18 through 80.

b

Regression equation: the regression equation with the calculated values for intercept A and slope B according to Passing & Bablok (1983). The equation converts the

dose calculated by ImPACT (x) to a new dose calculated by NCICT (y)
c
Systematic differences (intercept A): a measure of the systematic differences between the two methods. The 95% confidence interval for the intercept A tests the
hypothesis that A = 0. This hypothesis is accepted if the confidence interval for A contains the value 0. If the hypothesis is rejected, then it is concluded that A is
significantly different from 0 and the methods differ by a constant amount. Significant differences are shown in shaded cells.
d
Proportional differences (slope B): a measure of the proportional differences between the two methods. The 95% confidence interval for the slope B tests the hypothesis
that B = 1. This hypothesis is accepted if the confidence interval for B contains the value 1. If the hypothesis is rejected, then it is concluded that B is significantly
different from 1 and there is a proportional difference between the two methods. Significant differences are shown in shaded cells.
e
Random differences (residual standard deviation RSD): a measure of the random differences between the two methods. 95% of random differences are expected to lie
in the interval -1.96 RSD to +1.96 RSD. If this interval is large, the two methods may not be comparable. Significant differences are shown in shaded cells.
f

Linear model validity: the CUSUM test for linearity is used to evaluate how well a linear model fits the data. Where p<0.05 there is significant deviation from linearity.
Passing Bablok regression assumes linearity, therefore results are not shown.
https://doi.org/10.1371/journal.pone.0217816.t002

pronounced for females than males. The inset pie charts generally show a similar distribution
of cancers over the lifespan as a result of CT scanning for results generated from ImPACT
compared to NCICT dosimetry estimates for all protocols. The chest protocol shows the most
variation, with some difference in the proportion of cancer attributed to lung, colon and thyroid cancer.
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Fig 4. Lifetime attributable risk of cancer incidence for a) males and b) females exposed to radiation associated with an abdomen
pelvis CT scanning protocol as calculated using ImPACT or NCICT software. Figure inset shows the average distribution of cancers
across the lifespan (18–80 years) for each type of software (percentage contribution <4% are not annotated).
https://doi.org/10.1371/journal.pone.0217816.g004

Discussion
For the majority, but not all, of the organs used in epidemiological studies of cancer incidence,
the NCICT software (voxelised phantom) provides higher estimates of organ dose among
three different scanning protocols compared to the ImPACT software (mathematical phantom). The smallest percentage differences were generally seen among those organs that are
included in their entirety in the scan region. These are stomach, liver, bladder, colon, uterus
and ovaries for the abdomen/pelvis protocol and lung and breast for the chest protocol, with
larger percentage differences seen for organs further away, or on the boundary of the scan
region. The head protocol, for which most of the organs considered were outside the scan
region, the percentage difference between the software results are highest. This is a general
observation, and some deviation does occur. Within the chest protocol among females, the
uterus and ovaries (outside of the scan region) had percentage differences equal to or smaller
than the within-scan organs, breast and lung. These results showing greater percentage differences depending on the proximity of the organ to the scan region are consistent with previous
studies comparing software using mathematical and voxelised phantoms.[22, 27]
The differences in the results may be largely explained by the anatomical variation between
the phantoms with estimated radiation dose sensitive to the shape, size and position of the
organ.[22] As stated previously, consistency of the scan positions between the phantoms was
challenging due to the anatomical, size and/or postural variation. This is likely to have had
greatest impact on the boundary organs. Direct comparison with the values of the results from
other studies comparing software using voxelised and mathematical phantoms are likely to be
meaningless due to these factors as well as differences in scanning parameters, and other characteristics of the software. Through linear regression modelling we present formulae to convert
the results of the two software packages, however it is evident that this is an impractical application for the reasons provided above. While the results of the two different software programs
are comparable (i.e. the residual standard deviation was low), the models differ between organs
and between protocols. These conversion formulae are likely to apply only to these very specific scan regions, parameters and specific software used in our study.
Software programs based on mathematical phantoms are still available and estimates of the
lifetime attributable risk of cancer following CT radiation have relied on organ dose estimates
calculated from dosimetry software based on these mathematical phantoms as recently as
2015. [2, 7, 8, 11, 12, 37] This is despite the 2009 ICRP recommendation to use voxelised phantoms.[20] Our data demonstrate disparity in estimated cancer incidence with NCICT (voxelised phantom) calculated doses resulting in cancer estimates 2.9% to 6.6% higher in males and
14.8% to 16.3% higher in females for the abdomen/pelvis protocol across the lifespan. This disparity was greater for the chest protocol, with NCICT (voxelised) cancer incidence estimates
7.6% to 19.7% higher in males and 12.9% to 26.5% higher in females compared to ImPACT.
The head protocol was the only protocol for which the overall cancer incidence estimates were
lower for the NCICT (voxelised) software, but had the greatest disparity in results—in excess
of 30% at times. This can be attributed to the much higher dose estimate for bone marrow in
the ImPACT software, with leukaemia accounting for approximately 80% of all cancers resulting from the CT scan.
The extent to which these radiation dose estimates impact the results must be considered
within context. Uncertainty exists not only in dose assessment, but, perhaps more so, within
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Fig 5. Lifetime attributable risk of cancer incidence for a) males and b) females exposed to radiation associated with a chest CT
scanning protocol as calculated using ImPACT or NCICT software. Figure inset shows the average distribution of cancers across the
lifespan (18–80 years) for each type of software (percentage contribution <4% are not annotated).
https://doi.org/10.1371/journal.pone.0217816.g005

the data on the health effects of radiation exposure. Coefficients used to quantify the risk of
cancer as a result of CT radiation exposure are subject to revision and based on epidemiological studies that have inherent limitations. The BEIR VII risk coefficients used in the current
study, as with other sources,[21] have largely been derived from Japanese atomic bomb survivors, supported by smaller studies on health effects among those exposed to radiation medically and occupationally.[21, 28] The characteristics of these studied populations and their
radiation exposure are unlikely to be directly transferable to the population of interest. As an
example, baseline risks for many cancer sites in the United States, for which the BEIR VII coefficients have been adapted, are substantially different to those in Japan, impacting the attribution of risk. Furthermore, exposure among atomic bomb survivors, as well as in other studies,
has often been at high doses, unlike the low dose of CT.[28] As a result assumptions have to be
made about “exactly how radiation exposure increases the risk of cancer” and how to transfer
risk between populations.[28] The reliance on assumptions and subjective opinion has led to
healthy debate about these data. [38, 39] Many more sources of uncertainty, and examples, in
the risk estimates for radiation induced cancer have been described.[40]
Table 12–13 on page 291 of the BEIR VII report provides subjective confidence intervals
around the whole body cancer risk from radiation exposure. In males, it is estimated that there
are 800 excess cases of cancer (all solid cancer) from exposure to 0.1 Gy, with subjective confidence intervals of 400 and 1600. In females for the same exposure, excess cases are 1300 (CI,
690, 2500). As a ratio, the subjective confidence intervals for leukaemia are broader, with a
point estimate of 100 (CI 30, 300) for males and 70 (20, 250) for females.[28] If we consider
these ratios to apply to our results, the real cancer incidence resulting from our estimated radiation doses may be between a third and threefold of those estimated for leukaemia, or between
half and twofold of those estimated for all solid cancers. However, the percentage difference
between the estimates of cancer incidence resulting from each software program remains the
same regardless of the cancer risk coefficients. It is arguable that the uncertainty in health
effects of radiation exposure surpasses any concerns regarding the disparity between the software dose estimates.
In addition to the uncertainty of these risk estimates, this study has a number of limitations
related to assumptions made about anatomical position, the required manipulation of data to
normalise CTDIvol, scan length variation and the assumptions made to categorise organs into
“other” in ImPACT compared to NCICT. It is evident from the literature, and these limitations, that any attempt to quantify population cancer incidence attributable to radiation exposure is subject to great uncertainty. For this reason, cancer incidence estimates may be more
meaningful for relative comparison within studies in which assumptions and dosimetry software are consistent. What may be most important in the literature, other than how dose is estimated, is that methodology is described comprehensively and consistently to improve
transparency, reproducibility and scientific value, with clear indication of the type of software
and phantom used for dose estimates. Reporting guidelines have been developed for these reasons in other areas, such as CONSORT for randomised trials or RECORDS for Monte Carlo
radiation transport studies.[41] Comparison with other studies should also be undertaken
with care and overall uncertainty must be emphasised. In terms of policy implications, our
results suggest lower cancer incidence than previously thought as a result of head scans, but
higher incidence—more so for females—for both abdomen/pelvis and chest scans.
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Fig 6. Lifetime attributable risk of cancer incidence for a) males and b) females exposed to radiation associated with a head CT
scanning protocol as calculated using ImPACT or NCICT software. Figure inset shows the average distribution of cancers across the
lifespan (18–80 years) for each type of software (percentage contribution <4% are not annotated).
https://doi.org/10.1371/journal.pone.0217816.g006

Conclusion
Previous studies estimating cancer incidence using mathematical phantoms remain valid.
However when the results of these studies are compared to more recent, or future, studies
using voxelised and/or hybrid phantoms, the role of different software in the calculation of
results must be considered. Definite comparisons should only be made where dosimetry and
cancer estimates can be recalculated using the same software. Where this is not feasible, care
must be taken not to overlook the potential role of the change in software on outcomes. It is
clear that any change, or lack of change, in radiation dose or cancer risk may be attributable to
the type of software and phantom used, rather than—or in addition to—changes in scanning
practice. In line with the recommendations of the ICRP, new studies should aim to use software based on the more anatomically realistic voxelised phantoms. Studies using dosimetry
software to estimate radiation dose should describe the software comprehensively to facilitate
comparison with both past and future research.
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